Has Eli Lilly Stock Peaked?
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...
Shares of Wells Fargo rose 3.9% after the San Francisco bank’s fourth-quarter profit of $1.43 a share beat expectations of $1 ...
Lilly anticipates revenue growth contributions in 2025 from new Lilly medicines such as Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback